Akso Health (US:AHG)2025-03-28 20:05Financial Performance - Total revenues for the six months ended September 30, 2024, were $6,935,950, a significant increase from $894,768 in the same period of 2023, representing a growth of approximately 675%[5] - Net loss attributable to Akso's shareholders for the six months ended September 30, 2024, was $586,632, compared to a net loss of $3,457,657 for the same period in 2023, indicating a reduction in losses[5] - The company reported a gross profit of $192,743 for the six months ended September 30, 2024, compared to $38,830 for the same period in 2023, representing an increase of about 396%[5] - Operating expenses for the six months ended September 30, 2024, were $733,457, a decrease from $2,354,678 in the same period of 2023, indicating a reduction of approximately 68.8%[5] - The total net revenues for the six months ended September 30, 2024, after tax and surcharges, were $6,934,191 compared to $893,583 in the same period of 2023[46] - The Company recorded a loss from discontinued operations of USD 3,905 for the six months ended September 30, 2023, with no revenues reported for the same period in 2024[85] Assets and Liabilities - Total current assets decreased to $100,213,861 as of September 30, 2024, from $142,018,117 as of March 31, 2024, reflecting a decline of approximately 29.4%[2] - Cash and cash equivalents increased to $91,367,333 as of September 30, 2024, compared to $85,174,017 as of March 31, 2024, showing a growth of about 7.4%[2] - Total liabilities rose to $12,298,251 as of September 30, 2024, from $3,593,923 as of March 31, 2024, marking an increase of approximately 242%[2] - The total shareholders' equity increased to $200,651,653 as of September 30, 2024, from $138,424,194 as of March 31, 2024, reflecting a growth of approximately 45%[2] - The allowance for uncollectible accounts receivable was $7,720,556 as of September 30, 2024, slightly down from $7,770,556 as of March 31, 2024[49] - The Company reported accounts receivable of USD 8,128,790 as of September 30, 2024, with an allowance for uncollectible accounts receivable of USD 7,720,556, resulting in net accounts receivable of USD 408,234[86] Business Operations and Strategy - The Company plans to open 2 vaccine research centers and 100 radiation oncology centers on the U.S. east coast to serve cancer patients[12] - In April 2024, the Company acquired 50% equity interests in Tianjin Wangyi Cloud Technology Co., Ltd., and later acquired an additional 25% equity interests from minority shareholders, increasing its stake to 75%[12] - The Company has ceased its P2P and micro-lending businesses since 2019 and completed the disposition of its P2P business on December 30, 2020[11] - The Company established three medical device sales centers in the U.S. in January 2022 and began sales in the Chinese market in April 2022[12] - The Company began its marketing promotion business in the car insurance industry in April 2024, indicating a strategic expansion into new markets[38] - The Company has reclassified revenues, costs, and expenses related to the social e-commerce business as discontinued operations in its financial statements[17] Financing Activities - The company completed a private placement raising $62,568,014 during the six months ended September 30, 2024, contributing to its financing activities[10] - The Company raised approximately US$14 million from a securities purchase agreement on October 17, 2023, to be used for working capital and general corporate purposes[20] - The Company entered into a securities purchase agreement on January 17, 2024, to sell 160,826,730 units at a price of $0.3317 per unit, raising approximately $53.35 million for working capital and general corporate purposes[112] - On March 5, 2024, the Company agreed to sell 37,100,000 ADSs representing 111,300,000 ordinary shares and warrants for gross proceeds of approximately $49.34 million[114] - The Company completed a securities purchase agreement on June 27, 2024, selling 220,000,050 units at $0.2844 per unit, generating approximately $62.6 million for working capital and general corporate purposes[116] - On October 24, 2024, the Company entered into a securities purchase agreement to sell up to 361,290,000 units at $0.369 per unit, aiming to raise approximately $133.32 million for the expansion of its new healthcare services business[130] Compliance and Accounting - The Company’s financial statements are prepared in accordance with U.S. GAAP, and significant accounting estimates include revenue allocation and valuation of share-based compensation[30] - The Company believes its contractual arrangements with VIEs are compliant with PRC laws, although uncertainties in the legal system could impact its ability to enforce these agreements[24] - The Company has a full valuation allowance on net deferred tax assets for the six months ended September 30, 2024 and 2023, indicating uncertainty regarding realization[65] - The Company has no significant unrecognized uncertain tax positions as of September 30, 2024, and does not expect changes in unrecognized tax benefits over the next twelve months[67] Market Performance - Revenue from sales of medical devices was $415,020 for the six months ended September 30, 2024, a decrease of 53.7% compared to $894,768 in the same period of 2023[46] - Revenue from marketing promotion services reached $6,520,930 for the six months ended September 30, 2024, marking the first reporting of this revenue stream[46] - There were no sales returns reported since the start of the medical device business, indicating strong demand and customer satisfaction[43][44] - The weighted average number of ordinary shares outstanding increased to 699,050,796 for the six months ended September 30, 2024, compared to 68,598,050 for the same period in 2023[19] - As of September 30, 2024, the total noncontrolling interest amounted to USD 87,323, compared to USD 56,810 as of March 31, 2024, indicating a significant increase[69]